Search for a trial

Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies (study 208750)

This study has been transitioned to CTIS with ID 2024-513033-21-00 check the CTIS register for the current data. Primary:• To monitor participants for delayed AEs associated with administration of autologous cells that have been genetically modified…

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, alone or in combination with other agents, in Participants with Advanced Tumors (study 209012)

Primary:To assess the safety, tolerability and determine recommended phase 2 dose (RP2D) of NY-ESO-1 and LAGE-1a specific T cells, alone or in combination with other agents, in HLA-A*02-positive participants with NY-ESO-1 and/or LAGE-1a positive…